Tag Archives: Jeffrey Duchemin

Lots Of Options – Harvard Bioscience Further Details Its Executive Comp

Harvard Bioscience (HBIO) recently completed the spinoff of its regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technologies (HART). As we previously noted, the parent’s CEO and other top management moved to the spinco, creating a leadership void. The posts have since been filled and the company recently announced the details of some further ‘inducement grants’ for its new management team. Here… Read More »

A HART-felt Farewell: Harvard Bioscience Board Approves HART Spin

Harvard Bioscience Inc’s (HBIO) board of directors approved the spinoff of its regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology. The spin is set to take place on November 1st with HBIO shareholders receiving 1 share of the new company for every 4 shares of HBIO owned. The new company will trade under the ticker ‘HART’ and a when… Read More »